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Abstract
HIV-1 RNA has become the standard for monitoring anti-
retroviral therapies. Dogma predicts, however, that a
viral protein like p24 should be at least as good a marker
of HIV disease activity, provided that it is measured with
sufficient sensitivity and accuracy. Simple modifications
including use of a more efficient virus lysis buffer, heat-
mediated destruction of antibodies interfering with anti-
gen detection, and tyramide signal amplification for
increased sensitivity have highly improved the HIV-1 p24
antigen assay. The p24 antigen assay is inferior to RT-
PCR in detecting viral particles, but the presence of
extraviral p24 antigen in most samples makes largely up
for this. p24 antigen testing is similarly sensitive and spe-
cific in diagnosing pediatric HIV infection, in predicting
CD4+ T cell decline and clinical progression at early and
late stage of infection, and suitable for antiretroviral
treatment monitoring in both adults and children. Nota-
bly, p24 antigen was measurable even in patients with
stably suppressed viremia, and its concentrations were
correlated negatively with the concentrations of CD4+ T
cells and positively with the concentrations of activated
CD8+ T cell subsets. p24 antigen is an excellent marker of
HIV expression and disease activity and can be used in
the same fields of application as HIV RNA is used. The
test is validated for subtype B, but requires further stud-
ies for non-B subtypes.
Copyright © 2003 S. Karger AG, Basel
The demonstration that drugs that block HIV replica-
tion can halt and even partially reverse the progression of
HIV-infected persons towards destruction of the immune
system, AIDS and death [1–9] and that discontinuation of
antiretroviral treatment (ART), or viral mutation leading
to loss of its efficacy, is followed by a rapid rebound of
viral RNA in plasma and renewed loss of CD4+ T lym-
phocytes [10, 11] are clear proof of the concept that the
amount of the viral pathogen in an infected person, the
so-called viral load, determines disease outcome.
Favored by the development of highly efficient ampli-
fication techniques such as polymerase chain reaction
(PCR), procedures for quantifying viral nucleic acids, in
particular the viral RNA in plasma, have become stan-
dard tools for viral load assessment. It has been demon-
strated that the concentration of HIV RNA in plasma is
predictive of CD4+ T cell decline, progression to clinical
AIDS and survival [10, 12–15]. Consequently, HIV RNA
in plasma has become a major endpoint parameter for
clinical evaluation of ART regimens and for monitoring
therapy in individual patients [16–18].
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The dogma that the molecular mechanisms of viral
pathogenesis are mainly based on viral proteins remains,
however, unrefuted despite the impressive advancements
in nucleic acid-based tests, and it predicts that a viral pro-
tein should be as good a marker of disease activity as is the
viral RNA, provided that it can be measured with suffi-
cient sensitivity and accuracy. Some early studies investi-
gating patients soon after seroconversion indeed have
reported that detectability of p24 antigen was a stronger
predictor of progression to AIDS than was HIV-1 RNA
concentration [19, 20], but all studies performed at that
time showed less frequent detection of p24 antigen than of
HIV-1 RNA, demonstrating a true problem of sensitivity
[19–22]. During the past decade the antigen test has been
greatly improved, however, and sufficient data have now
accumulated to justify reassessment of antigen testing in
HIV disease.
Principle and Problems of Antigen Detection
The test principle consists of binding the p24 antigen
present in a sample to p24-specific, mono- or polyclonal
‘capture’ antibodies coated onto a solid support. Un-
bound sample components are washed away, and bound
antigen is detected with another p24-specific ‘tracer’ anti-
body to which an enzyme (horseradish peroxidase or alka-
line phosphatase) is conjugated capable of signal genera-
tion when combined with a suitable substrate (fig. 1a).
For confirmation of a reactive diagnostic result, the sam-
ple must be subjected to a neutralization assay. This
means that the antigen test is repeated in the presence of
high-titered HIV-specific antibodies. These bind the anti-
gen in immune complexes, thus preventing its detection
in the test (fig. 1b).
This test system is frequently confronted with three
problems. One is the presence of p24-specific antibodies,
which as in the neutralization assay immune-complex the
antigen, thus causing underdetection or false-negative
results [23–25]. A second problem is the presence of
immunoglobulin-specific, rheumatoid-factor-like anti-
bodies which may bridge the capture and the tracer anti-
bodies of an antigen test and thus cause overdetection or
false-positive results (fig. 1c). This type of problem may
be present when in the neutralization test the addition of
HIV-specific antibodies to the test sample does not result
in a higher degree of signal reduction than does the addi-
tion of antibodies from an HIV-negative control. A third
problem is the low sensitivity of the test compared to
nucleic acid-based methods [26].
Fig. 1. Principle of antigen testing and interference by antigen-spe-
cific or Ig-specific antibodies (for explanation see text) [with permis-
sion, 67].
How to Improve p24 Antigen Tests
Improvements introduced into p24 antigen testing
were primarily aimed at improving detection of immune-
complexed antigen. Acidification or base treatment leads
to a significant, though incomplete, release of antigen,
thus increasing the proportion of antigen-positives signifi-
cantly [27]. Experience shows, however, that a consider-
able part of antigen cannot be freed from complexes or
reassociates again when the pH of the sample is neutral-
ized in order to allow binding of the antigen to the capture
antibody. In addition, these treatments will release rheu-
matoid factors from preformed immunoglobulin-anti-im-
munoglobulin complexes, thus aggravating the problem
of overdetection or false positivity [28]. The combination
of these two effects whose extent in a given sample cannot
be predicted prevents an accurate measurement of the
true concentration of p24 antigen in a sample.
Heat Denaturation Eliminates Antibody Interference
Interference by antibodies (problems 1 and 2) can be
eliminated efficiently by heat-mediated destruction of the
three-dimensional structure of antibodies. Boiling the di-
luted sample for 5 min abolishes all antigen binding by
antibodies, but leaves the p24 antigen reactive in tests
that feature reagents (mono- or polyclonal antibodies for
capturing and tracing) which recognize heat-denatured
antigen. This effect has been demonstrated in numerous
experiments involving both artificial immune complexes
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Fig. 2. Principle of tyramide-mediated sig-
nal amplification of ELISA [34]. The tracer
antibody which is labeled with horseradish
peroxidase H (HRPH) is used as a catalyst
antibody for the activation of the biotin
tyramide reporter molecule. The activated
reporter binds to tyrosine residues of any
immobilized protein. Added HRPH-labeled
streptavidin thus finds a highly increased
number of targets, thereby generating an en-
hanced signal [with permission, 68].
Table 1. Virus component detection by
signal-amplification-boosted p24 antigen
ELISA of heat-denatured plasma and
PCR for HIV-1 RNA [with permission, 35]
Classification p24 antigen ELISA
positive/tested %
HIV-1 Monitor version 1.0
positive/tested %
By CDC 93 category
A 71a/74 95.9 46/50 92
B 50a/51 98.0 31/32 96.9
C 57/57 100 35/35 100
By CD4+ cell category
1 (6500/Ìl) 12/14 85.7 6/6 100
2 (200–499/Ìl) 52a/53 98.1 34/38 89.5
3 (!200/Ìl) 114a/115 99.1 72/73 98.6
Total 178/182 97.8 112/117 95.7
a After subtraction of one reactive sample not confirmed by neutralization.
and natural patient samples [29–31]. Thus, this simple
measurement permits to determine a sample’s true anti-
gen content.
The practical value of this first heat-denaturation-
based procedure was established by a study of children
born to HIV-1-infected mothers. Due to transplacentar
transport of maternal IgG such children have usually high
concentrations of HIV-specific IgG antibodies, resulting
in immune complexation of all p24 antigen. In this retro-
spective study the procedure’s specificity in 390 samples
from uninfected children born to HIV-positive mothers
was 96.9% after initial testing and 100% after neutraliza-
tion. Diagnostic sensitivity among 125 samples from
infected children was, at a detection limit of 2 pg/ml,
96.0% (97% of which neutralizable) compared with
47.7% for regular antigen (76% neutralizable), 96% for
PCR for HIV-1 DNA, and 77% for virus culture [32]. The
study also found low levels of p24 antigen in 29% of cord
blood sera, a postnatal increase to levels that were during
the first 6 months of life – i.e., the time of the primary
infection – inversely correlated with survival, and persis-
tence of antigenemia in all children thereafter. These find-
ings were in perfect agreement with the later demonstra-
tion by others that high viral RNA levels at birth and dur-
ing primary viremia were associated with early onset of
symptoms and rapid disease progression [33].
Increase of Sensitivity by Tyramide Signal
Amplification
Despite its high diagnostic sensitivity in pediatric HIV
infection the procedure was not sufficiently sensitive, as
shown by the fact that only 22% of the mothers of these
children tested positive [32]. The antigen assay was there-
fore boosted by the simple, commercially available tyram-
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Fig. 3. Overview on the effects achieved by the various measures
used to improve antigen detection. The box plot rendition of the
reactivity of each sample is a percentile-based analysis, in which the
five horizontal lines represent, from bottom to top, the 10th, 25th,
50th, 75th and respectively 90th percentile and outrunners are plot-
ted individually. UD-Ag = Undenatured antigen; ADD-Ag = antigen
after acid disruption of immune complexes; HD-Ag = heat-dena-
tured antigen; HD-Ag ELAST = heat-denatured antigen combined
with detection by ELAST tyramide signal amplification boosted
ELISA [with permission, 35].
ide signal amplification system whose principle is shown
in figure 2 [34]. A comparison of paired serum and plas-
ma samples from 245 adult HIV-1-infected individuals of
all stages of chronic infection furthermore showed that
plasma contains more p24 antigen than serum (fig. 3). In
combination, heat denaturation, use of plasma instead of
serum and tyramide signal amplification led to a proce-
dure that had the same diagnostic sensitivy as the Roche
Amplicor HIV-1 Monitor® version 1.0 which had a detec-
tion limit of 200–400 HIV-1 RNA copies/ml in our hands
(table 1) [35].
Further Improved Antigen Detection by a Better Virus
Lysis Buffer
Since we discovered that certain samples with HIV
RNA concentrations that should have permitted detec-
tion of the particle-associated antigen were negative in the
assay we replaced the Triton X-100 buffer of the kit by
one containing a mixture of different detergents [36]. Pre-
treatment of samples with this buffer results in signifi-
cantly improved detection of particle-associated antigen,
as also found by others [37].
p24 and HIV RNA Are Related, but Different
Viral Markers
The production and release of p24 and particle-associ-
ated RNA are biologically tightly linked. They are both
derived from unspliced viral mRNA, and p24 is a compo-
nent of the viral protein precursors Pr160gag-pol and
Pr55gag, thus being stoechiometrically linked with another
precursor component, the nucleocapsid p9, which is di-
rectly involved in encapsidation of viral RNA into the
particles. p24 is an important structural component of the
retroviral particle and estimated to be present at 2,000–
4,000 molecules in each virion [38]. It is clear that
increased viral transcription will normally lead to in-
creased intracellular concentrations of both genomic
RNA and viral proteins; this in turn will be followed by
increased particle formation and release, leading to in-
creased extracellular concentrations of the two markers.
On the other hand, destruction of virus-producing cells by
viral or immune cytopathicity will increase the extracellu-
lar concentrations of viral proteins, while not leading to a
likewise increased concentration of HIV RNA. Similarly,
destruction of virus particles should lead to instant degra-
dation of the enclosed viral RNA by RNases present at
high concentrations in all body compartments, while the
enclosed viral proteins should be more resistant and thus
persist outside the particle. In support of this we have
been able to measure p24 antigen in 92.5% of serum sam-
ples stored for 10 years and found the p24 concentrations
to be significantly correlated with the risk of progression
to AIDS, while HIV-1 RNA was degraded to undetectable
levels in more than 70% of the samples. Thus, although
we expect an overall positive correlation of the concentra-
tions of HIV RNA and viral protein, e.g. the p24 antigen,
which indeed has been found in all published compari-
sons [35, 39–45], there are situations in which a positive
correlation cannot be anticipated.
Viral RNA and p24 Antigen during the Natural Course
of the HIV Infection
Figure 4 summarizes the course of HIV RNA, p24
antigen and immunological markers during HIV infec-
tion. In acute infection, replication of HIV within the
lymphatics, which harbor 98% of the body’s lymphocytes,
causes in the absence of a specific immune response a rap-
id increase in the production and release of virus and
virus-infected cells [12, 46–49]. Peak concentrations of
viral RNA in plasma may vary widely, from 104 to more
than 107 copies/ml [50, 51].
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Fig. 4. Schematic overview of CD4+ T lym-
phocytes, HIV RNA, p24 antigen and im-
munological parameters in the course of the
disease. Viral markers in plasma depend not
only on production rates in the lymphoid tis-
sues [also influenced by HIV-specific cyto-
toxic T lymphocyte (CTL) activity], but also
on retention mechanisms exerted by an in-
tact follicular dendritic network in combina-
tion with the humoral immune response.
Note the difference in viral RNA and p24
antigen concentrations in final disease.
It is now clear that HIV RNA is the first viral marker
detectable in acute infection. p24 antigen on average
becomes positive 7 days after a HIV RNA test with a
detection limit of 50 copies/ml. At the time of antigen
conversion the concentration of viral RNA on average is
10,000 copies/ml [51]. As many as 5,000 virus particles
are thus needed before the p24 antigen enclosed in these
can be detected. Since there are no HIV-specific anti-
bodies, there will be no immune-complexed p24 antigen.
Virus levels decrease with the onset of the antiviral
immune response, namely, the production of HIV-spe-
cific cytotoxic T lymphocytes. Moreover, after serocon-
version, antivirus antibodies that bind to virus particles
and to which complement is fixed will increase virus
retention on follicular dendritic cells of the lymphoid tis-
sues. These cells, whose numerous processus form a dense
network, carry complement receptors at high density and
thus retain large quantities of immune-complexed infec-
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Fig. 5. p24 antigen in plasma originates from different sources.
a Evidence for presence of p24 outside viral particles. Ultracentrifu-
gation of plasma from patients in the chronic stage of HIV infection,
while removing all viral RNA and reverse transcriptase activity (not
shown), leaves most of the p24 antigen in the supernatant, thus indi-
cating that most of the detectable antigen is not associated with viral
particles. b Possible sources of p24 antigen and HIV-1 RNA in plas-
ma. p24 antigen may originate from several sources including the
structural protein of intact or defective viral particles present in the
sample or released from particles degraded while entangled in the
follicular dendritic cell network of the lymphatics. p24 antigen may
also be released from HIV-producing cells or leak from cells killed
either by viral or immune-mediated cytotoxicity. p24 antigen con-
centration in plasma may therefore be more representative of the
total viral load in the body than is the HIV-1 RNA in plasma, which
originates exclusively from intact circulating particles.
tious virions [52–54]. Since the half-life of virus particles
is only a few hours [55], if not minutes [56], a large part of
trapped virions will be degraded and their viral RNA
digested. In agreement with this, the viral RNA load in
this phase is high in lymphoid tissues, but low in plasma
[57].
After the peak of acute infection, concentrations of
virus in blood are stabilized on individually different lev-
els, the so-called set point, which is strongly associated
with disease progression [14, 20, 50, 58]. During asymp-
tomatic infection, the CD4 T cell count decreases contin-
uously at an individually different but constant rate. A
marked increase in the level of viral RNA in plasma is
seen in advanced immunodeficiency when the CD4 T cell
count has dropped to below 200/Ìl. This is usually inter-
preted as a final complete breakdown of the mechanisms
that previously maintained a certain control of virus repli-
cation.
The concentration of p24 antigen in this chronic phase
of infection largely follows that of the HIV RNA, but with
two important differences. First, while all viral RNA in
plasma is located inside viral particles, most p24 antigen
is found outside. This is demonstrated by ultracentrifuga-
tion experiments in which very little of the total p24 anti-
gen present in plasma could be pelleted (fig. 5a). In con-
trast, HIV RNA and reverse transcriptase could be quan-
titatively recovered from the ultracentrifugation pellet
(not shown). The most obvious source for the extraviral
p24 antigen are the numerous virions destroyed while
sequestered in the lymphatics, but release from virus-pro-
ducing cells or leakage from cells destroyed by viral or
immune-mediated cytotoxicity is also possible (fig. 5b).
Another notable difference is seen in advanced disease
when HIV RNA exhibits the above-mentioned marked
increase (fig. 4). Cross-sectional studies have shown that
there is no concomitant increase of p24 antigen. Instead,
p24 antigen concentrations are similarly high in patients
exhibiting 100, 200 or 350 CD4+ T cells/Ìl, while patients
with 50/Ìl or below exhibit slightly lower antigen concen-
trations [41]. It is likely that the destruction of the follicu-
lar dendritic cell network, which is typically present in
advanced HIV disease (bottom of fig. 4), leads to a
decreased retention and destruction of particles, and
more virus will reach the peripheral blood [59]. Thus, the
apparent final rise of viral RNA in plasma (top of fig. 4)
may rather be due to a gradually increasing redistribution
of virus from the lymphatics to the bloodstream than
represent a true increase in virus production. A reduced
virus production in the final stage, as suggested by the
decreasing concentrations of p24 antigen in plasma,
would be in keeping with the total destruction of the
CD4+ T cells.
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Table 2. Diagnostic sensitivity of HIV-1
detection methods in pediatric samples
[with permission, 40]
Age Antigen
neutralized
In-house PCR
viral DNA
In-house PCR
viral RNA
HIV-1 Monitor
viral RNA
^10 days 6/12 (50) 5/12 (42) 3/7 (43) not donea
11 days to 3 months 10/10 8/8 7/7 6/6
13 to 6 months 19/19 12/12 12/12 9/9
16 months 191/191 66/66 26/26 120/120
110 days 220/220 (100) 86/86 (100) 45/45 (100) 135/135 (100)
The number of positive/tested samples is shown with the percentage in parentheses.
a The sample positive in the antigen assay but negative by in-house PCR for viral DNA or
RNA was also negative by the ultrasensitive HIV-1 Monitor version 1.5.
p24 Antigen and HIV RNA with Respect to
Different Clinical Questions
Besides diagnosis of HIV infection which in Europe is
increasingly done by means of combo tests that detect
both antibody and antigen, virus component tests are
needed for diagnosis of pediatric HIV infection, assess-
ment of a patient’s rate of disease progression, and control
of ART (initial response to treatment, diagnosis of treat-
ment failure). Studies addressing all these questions have
been done. For all antigen assays the HIV-1 p24 Core Pro-
file ELISA in combination with the ELAST® ELISA Am-
plification System (both available from Perkin Elmer Life
Sciences) was used. Unless stated otherwise Roche’s Am-
plicor HIV-1 Monitor® in versions 1.0 or 1.5 was used for
quantification of viral RNA. For diagnostic purposes,
qualitative in-house tests for viral DNA or RNA capable
of detecting a single copy of HIV-1 DNA or cDNA were
also used in early studies [32, 60].
Diagnosis of Pediatric HIV-1 Infection
A study conducted between 1994 and 1997 with pro-
spective analysis of p24, HIV-1 DNA and RNA investi-
gated the diagnostic sensitivity of p24 antigen and PCR-
based tests in 232 samples from 61 HIV-1-infected un-
treated children born to HIV-positive mothers in Switzer-
land (table 2) [40]. All tests were 100% positive above 10
days of age. Below 10 days, p24 was confirmed positive in
6 of 12 samples. DNA PCR and in-house PCR for viral
RNA both missed one of the samples positive for p24.
When retested by the HIV-1 Monitor version 1.5 ultrasen-
sitive assay with a detection limit of 50 copies/ml the sam-
ple was also negative. The diagnostic specificity of the p24
assay among 643 plasma samples from 246 uninfected
children born to HIV-1-positive mothers was 99.2% after
neutralization. Two (1.4%) of 141 samples tested with the
in-house method for viral RNA were false-positive result-
ing in a diagnostic specificity of 98.6%. Thus, p24 was
equal to RNA regarding diagnostic sensitivity and speci-
ficity in pediatric HIV-1 infection. The high sensitivity
and practical utility of this procedure were also confirmed
by others in children from Tanzania [61].
Diurnal Variation of HIV-1 p24 Antigen
Concentration in Plasma and Precision
Few data are available on precision of the p24 antigen
assay, but they suggest a higher precision than that of the
HIV-1 Monitor assay. Diurnal variation of plasma HIV-1
load at four different time points each during two differ-
ent days (a Friday and the following Monday) was studied
in five HIV-1-infected children with implanted intravas-
cular catheters after informed consent had been given.
The investigations demonstrated that the p24 antigen lev-
els had, with a mean log standard deviation (SD) that
amounted to 0.057 (range 0.02–0.11), less variation than
the HIV-1 RNA concentrations (mean log 0.108; range
0.07–0.15) [40]. In another study in which 8 different
specimens were tested 3–4 times in an assay, the mean log
SD of the antigen test was 0.07 compared to 0.11 for the
Roche HIV-1 Monitor assay [44].
Prediction of Disease Progression
The predictive value of p24 antigen concentration was
tested in two published studies. In a first, retrospective
study involving 169 chronically infected adult Swiss pa-
tients with a median CD4+ T lymphocyte count of 140
cells/Ìl (range 0–1,500), p24 antigen and HIV-1 RNA
concentrations were determined in a single sample col-
lected in 1993–1994 and the predictive value of these
markers regarding disease progression was compared.
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Follow-up data included at least one further CD4+ T lym-
phocyte count and assessment of the clinical stage with a
median observation period of 2.7 years (range 0.1–4.9). In
CD4-adjusted Cox proportional hazard models, both
RNA (p ! 0.005) and p24 antigen (p = 0.043) were signifi-
cant predictors of progression to AIDS. p24 was superior
(p = 0.032) to RNA (p = 0.19; nonsignificant) in predict-
ing survival. p24 was also a significant predictor of the
CD4+ decline in ‘CD4+-adjusted’ models and was equiv-
alent or superior to HIV-1 RNA depending on the group
analyzed and the statistical test employed [41].
The prognostic value of p24 antigen was confirmed in
a second study which involved first-visit plasma samples
from 494 mostly black IVDU from Baltimore, Md, USA.
This cohort had a median initial CD4+ lymphocyte count
of 518/Ìl; 90 of the patients (18%) progressed to AIDS
within 5 years. p24 antigen was strongly correlated with
both HIV-1 RNA, as determined by bDNA assay (r =
0.55; p ! 0.0001) and CD4+ lymphocytes (r = –0.34; p !
0.0001). p24 level 15 pg/ml predicted disease progression
comparable to cutoffs of !350 CD4+ lymphocytes/mm3
and 130,000 copies/ml HIV-1 RNA. Heat-denatured p24
antigen thus predicted subsequent clinical disease pro-
gression in early-stage HIV-1 infection, and was closely
correlated with both CD4+ lymphocyte and HIV-1 RNA
level [43].
ART Monitoring and Detection of Treatment Failures
The suitability of p24 antigen for ART monitoring was
investigated in both adult and pediatric infection of
patients in Switzerland. In a study of 23 adult patients
with advanced disease who received a new, indinavir-con-
taining treatment regimen, p24 antigen was detected as
sensitively as viral RNA, namely in 75.6% of the samples
(RNA 73.6%). Antigen and RNA levels in 79 samples pos-
itive for both markers correlated with R = 0.714 (p !
0.0001). This correlation was similar to that found in a
different study in which HIV-1 RNA levels were deter-
mined in parallel by two different methods, namely the
Amplicor HIV-1 Monitor and the NucliSens® HIV-1
RNA Quantitative Test [62]. Mean changes in levels of
p24 antigen and RNA at eight time points correlated with
R = 0.982 (p ! 0.0001; fig. 6). In individual patients, the
two parameters behaved similarly and in certain cases vir-
tually identically [39]. Similar results were found in a pro-
spective study of 25 children with a total of 230 analyzed
samples in Switzerland. Here, the correlation of RNA and
p24 antigen in individual samples was R = 0.658 (p !
0.0001). In most instances the treatment-induced changes
were more pronounced for HIV-1 RNA than for p24. p24
Fig. 6. Treatment-induced changes in concentrations of HIV-1 RNA
and p24 antigen. Logarithmized mean values B 1 standard deviation
are shown [with permission, 39].
levels showed significantly less variation than HIV-1
RNA [40]. Good correlation between HIV-1 RNA and
p24 antigen (R = 0.751, p ! 0.0001) was also observed
with sequential samples from patients infected mostly
with non-B subtypes [45].
We also investigated 34 Swiss patients who were en-
rolled in 1997 into two treatment studies in which they
were prospectively tested for viral RNA by the Roche
HIV-1 Monitor version 1.0 and p24 antigen [63]. The
data were evaluated regarding the response of these mark-
ers to ART and timely detection of treatment failures. We
found that p24 antigen was detectable in 75.8% of 178
samples and HIV RNA in 73.9% of 138 samples. Correla-
tion of the two markers was good (R = 0.744, p ! 0.0001).
Treatment failure, as defined by RNA concentrations,
occurred in 14 patients (fig. 7). Secondary treatment fail-
ures with RNA rebounds from undetectable levels to less
than 103 copies/ml in 2 patients with an undetectable
viral load and 103 HIV RNA copies/ml, respectively, at
baseline were not detected by p24 antigen. The two fail-
ures carried a low risk for secondary resistance mutations
and were, as demonstrated by retesting with a still more
sensitive p24 antigen assay, in principle detectable. The
other 12 failures were detected on average 29 days earlier
by p24 antigen than by RNA (p = 0.020), owing to slightly
more frequent testing for p24 antigen than for RNA (2.7
vs. 2.4 tests until detection of treatment failure). Average
costs of p24 antigen testing up to a failure were only
20.5% of those of RNA (p ! 0.0001).
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Fig. 7. Courses of HIV-1 RNA and p24 antigen in patients receiving ART and detection of treatment failure. Down-
facing arrows mark the point of failure detection by PCR for viral RNA, upfacing arrows by ELISA for p24 antigen.
Panels #B2 and #B13 do not contain upfacing arrows since the rebounds of p24 antigen in these patients were not
confirmed by the subsequent measurement [with permission, 63].
These findings should not be interpreted to suggest
that the p24 antigen test would be as sensitive as RT-PCR
in detecting virus that rises only slowly after a long period
of complete viral suppression. Complete suppression of
replication will with time also deplete the stores of im-
mune-complexed p24 antigen in the lymphatics. In the
absence of the extraviral background of p24 antigen a cer-
tain concentration of virus particles in plasma is needed
before p24 concentrations rise above the limit of detec-
tion, similar to the situation in acute infection (see below
and fig. 8).
p24 Antigen in Patients with Stably Suppressed HIV
RNA
The studies mentioned above demonstrate the use of
the p24 antigen assay for monitoring of newly initiated
treatments. We were also interested whether the assay
would be useful in patients whose HIV RNA was stably
suppressed by long-term ART. We therefore investigated
p24 antigen concentrations prospectively in 55 patients
whose viral RNA in plasma had previously been sup-
pressed for at least 6 months under antiretroviral combi-
nation therapy. During a median follow-up of 504 days,
CD4 counts increased by a median of 62 cells/year. By
both univariate and multivariate linear regression analy-
sis the level of p24 antigen, as expressed by the absor-
bance/cutoff ratio, was a significant inverse correlate of
both the CD4 count in a sample (p = 0.013) and its annual
change in a patient (p ! 0.0001). p24 retained significance
even among 48 individuals whose HIV-1 RNA, apart
from occasional blips, remained below 400 copies/ml.
Batchwise retesting of 70 samples from 5 such patients
with a further improved procedure showed measurable
p24 antigen in all but one sample and an inverse correla-
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Fig. 8. Schematic representation of differ-
ential courses of HIV RNA and p24 antigen
following initiation of ART leading to com-
plete virus suppression and loss of treatment
efficacy due to resistance mutation. Black
line = HIV RNA; grey line = p24 antigen;
dotted horizontal line = limit of detection.
a Situation in which initial HIV RNA and,
thus, particle-associated p24 is high com-
pared to extraviral p24 antigen. The sequen-
tial phases a–f are: both HIV RNA and p24
antigen (largely particle-associated) decrease
with same t1/2 (a); both markers still detect-
able; they decrease with different t1/2 (b);
only p24 antigen detectable due to longer t1/2
(c); both markers undetectable (d); viral
RNA first detectable in viral failure because
RT-PCR is more sensitive in detecting parti-
cles (extraviral stores of p24 antigen are de-
pleted) (e); both markers positive (f). b Situa-
tion in which both initial HIV RNA and
extraviral p24 are low: quick disappearance
of p24 antigen (a); only HIV RNA detectable
(c); both markers undetectable (d); slow in-
crease of HIV RNA after low-grade resis-
tance mutation leads to delayed increase of
p24 antigen, due to depleted stores (e, f).
c Virus suppression with HIV RNA concen-
tration remaining just below the detection
limit while p24 antigen, possibly fed by anti-
gen released in the lymphatics, remains de-
tectable at low concentration for a prolonged
period of time [36].
tion with both the CD4 count (p = 0.0331) and percentage
(p ! 0.0001), thus confirming the prospectively generated
data [36]. We have meanwhile also evaluated the relation-
ship of p24 antigen concentrations to subsets of CD8+ T
cells exhibiting the activation markers CD38 and/or
HLA-DR in these patients and found highly significant
positive correlations, even in a subgroup of samples in
which HIV RNA was undetectable in a test with a detec-
tion limit of only 5 copies/ml. Thus, the concentration of
p24 antigen is directly correlated with the number and
percentage of those cells that represent the hyperactiva-
tion of the immune system, which is considered a key ele-
ment of HIV pathogenesis [59]. These two studies demon-
strate that HIV RNA measured by RT-PCR is not per se a
more sensitive marker of HIV infection than is p24 anti-
gen, even though it is admittedly more sensitive in detect-
ing HIV particles [51].
Differential Course of HIV RNA and p24 Antigen
during Changes in ART
Since the half-life of virus particles is short, initiation
of efficient combination therapy in previously untreated
patients leads to a rapid reduction of HIV RNA in plasma
[10, 13]. The half-life of p24 antigen in the first phase of
effective treatment is similar to that of HIV RNA, thus
representing the decrease of particle-associated antigen
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[63]. Similar to HIV RNA a second, slower decay phase
was found which had a half-life of 42 B 16 days. In con-
trast to HIV RNA, the antigen detected in this phase is
not particle-associated, but consists of immune-com-
plexed or free extraviral protein. As demonstrated by the
two abovementioned studies and other, not yet published
work such protein may still be present well after HIV
RNA has become undetectable by the most sensitive
assays. Based on the initial ratio of particle associated to
extraviral p24 antigen, the efficacy of ART and the time
point and severity of resistance mutations, different pat-
terns of relationships between HIV RNA and p24 antigen
during treatment follow-up can be found (fig. 8).
Detection of Viruses of Non-B Subtype
The results described above indicate that p24 is com-
parable to HIV-1 RNA when used for diagnosis of pediat-
ric HIV-1 infection, as a marker of disease activity or pro-
gression or for treatment monitoring in Switzerland or the
US where subtype B infections prevail.
Antiretroviral therapy is now becoming increasingly
available to patients living with HIV/AIDS in many
developing countries, due to significant reductions in
antiretroviral drug prices. There is thus a rapidly increas-
ing demand for inexpensive tests capable of assessing the
need for antiretroviral therapy in a given patient and of
monitoring the effect of such treatment. It is estimated
that ART costs will be in the order of USD 300 per patient
and year. The high costs of the above-described tests
which currently amount to about USD 50–100 per test
and the fact that at least two such tests, if not four, will
have to be performed every year seem to preclude their
use in the many less affluent countries and societies. In
addition, these molecular-based tests require technically
advanced and expensive facilities and equipment, as well
as highly trained laboratory personnel. It is thus difficult
to imagine that these tests could be sensibly used for mon-
itoring of ART in developing countries. An inexpensive
method for measuring the virus load could greatly im-
prove the diagnosis and treatment of HIV infection
worldwide.
With regard to a use of this test in developing coun-
tries, in particular Africa, it is important to assess the suit-
ability for non-B subtypes. Only limited data regarding
this issue are currently available. Lyamuya et al. [61]
found a high diagnostic sensitivity in diagnosing pediatric
HIV-1 infection in Dar es Salaam, Tanzania. Altogether,
123 of 125 samples from 76 PCR-positive infants were
positive for p24 antigen (sensitivity = 98.7%). HIV-1 p24
antigen was found in all 18 samples collected at 1–8
weeks, in 35 of 36 samples collected at 9–26 weeks, in all
40 samples collected at 27–52 weeks, and in 30 of 31 sam-
ples collected 52 weeks after birth. The sensitivity of the
assay was also assessed in a Swiss study of 103 individuals
likely to be infected by non-B subtypes [64]. The tests
assessed included three RNA-based assays including the
Amplicor HIV-1 Monitor 1.5, the Quantiplex version 2.0
(bDNA), the NucliSens (NASBA), an ultrasensitive re-
verse transcriptase assay called PERT assay [65] and the
improved p24 antigen assay. Subtyping was based on
sequencing in the env gene. p24 was more sensitive than
NucliSens or Quantiplex, but less sensitive than Amplicor
or PERT assay. A more detailed, quantitative comparison
showed that 2 samples with an HIV-1 RNA concentration
above 10,000 copies/ml (one subtype A and one subtype
C) were negative for p24 antigen. Other samples of these
subtypes were, however, well recognized, even some in
which HIV-1 RNA was not detectable or below the limit
of quantification (400 copies/ml). In particular, the p24
antigen assay was also positive in one subtype O sample
that was negative by all assays for HIV-1 RNA, but posi-
tive by the PERT assay. Good detection of subtypes A–F
and circulating recombinant strains was also reported by
others [44], and a group from Thailand recently reported
good results with using an antigen kit of a different manu-
facturer in combination with Perkin-Elmer’s tyramide
signal amplification step [66]. These data suggest that the
p24 antigen assay is not per se inferior to tests for HIV-1
RNA regarding recognition of different subtypes. How-
ever, this issue needs to be studied more extensively
before the test is routinely used in non-B areas, and
adjustments regarding the capture or tracer antibodies of
the kit or development of an entirely new kit may prove
necessary.
Sample Handling and Physical Stability of p24
Antigen
In an attempt to strengthen further the evidence for a
predictive value of p24 antigen we recently conducted a
study involving serum samples collected between 1989
and 1990 from 547 patients of all disease stages treated at
the Zürich University. The study intended to directly
compare the predictive values of HIV-1 p24 antigen and
HIV-1 RNA. Unfortunately, HIV-1 RNA was found to be
degraded in the majority of samples, and the study had to
be restricted to the assessment of p24 antigen alone. Of
the 547 samples, 92.5% had a p24 antigen concentration
above the cutoff; these samples exhibited the same con-
centration distribution as previously noted in another
study [41]. These data indicate that p24 antigen is much
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 3
:2
9:
47
 P
M
HIV-1 p24 Antigen Int Arch Allergy Immunol 2003;132:196–209 207
more stable than is viral RNA. In accordance with this
there is no need for special ‘plasma preparation tubes’,
expensive individual express delivery, and –70°C freez-
ers. Samples may be kept for several days at 4°C before
testing. Preliminary assessment of the effect of freezing-
thawing cycles has indicated that one such cycle leads to
about 3% loss of p24 antigen, with no further change after
the third cycle (unpubl. data).
Costs
In the absence of a kit which contained all necessary
ingredients for sample preparation, ELISA, and signal
amplification it was difficult to assess the price of this test.
Previous comparisons based on reimbursement by health
insurances in Switzerland arrived at a price of CHF 50
(USD 30) for the antigen test and CHF 275 (USD 167) for
a HIV-1 Monitor assay. A study performed in the US
quoted USD 8 for the antigen assay and USD 75 for the
HIV-1 Monitor assay including reagents and work [44].
Based on these data the costs of the p24 assay can be
expected to amount to 10–20% of those of a HIV-1 RNA
assay.
Conclusions
The different properties of p24 antigen and particle-
associated HIV RNA require that the comparative clini-
cal value of these markers is evaluated with reference to
distinct fields of application including diagnosis of pediat-
ric HIV infection, prediction of disease progression, and
monitoring of ART. A simple assessment of the sensitivi-
ty of antigen testing using samples previously found posi-
tive for HIV RNA (which is taken as the gold standard)
will not reveal that p24 antigen, even though it is less sen-
sitive in acute HIV infection, is as good a predictor of dis-
ease progression as is viral RNA. Such superficial evalua-
tions will also miss the point that p24 antigen correlates
significantly with immune parameters considered crucial
to HIV disease in patients in whom HIV RNA is no longer
detectable, since samples with undetectable HIV RNA
would be considered a priori to contain no HIV. In con-
trast, the studies reviewed here indicate that p24 antigen
is as relevant to the biology of HIV disease as is viral RNA
and that it is comparable to the latter with regard to sensi-
tivity and specificity, prediction of progression to AIDS
or death, and useful for monitoring of ART. Unlike
HIV-1 RNA measurement, this simple, considerably less
expensive and easily automatable procedure does not
require cumbersome sample transport and pretreatment
procedures. Further studies on p24 antigen are highly
warranted; in particular, they should aim at validating the
test for non-B subtypes.
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